MindImmune Licenses Preclinical Drug Discovery Programs from Lundbeck Will Develop Novel Therapeutics to Treat Neuropathic Pain and Huntington’s Disease Kingston, R.I., May 22, 2018 – MindImmune Therapeutics, Inc. and H. Lundbeck A/S(Lundbeck) today announced...
Lundbeck divests preclinical research programs Two programs outside Lundbeck’s areas of focus are transferred to MindImmune Therapeutics, Inc. H. Lundbeck A/S (Lundbeck) further focuses its preclinical research pipeline with the divestment of two research programs...